Holen Sie sich die Stockscreener-App
116.49
3.05%
3.45
Handel nachbörslich:
116.49
Monopar Therapeutics Inc Aktie (MNPR) Neueste Nachrichten
(MNPR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Monopar Therapeutics (NASDAQ:MNPR) Cut to Sell at Wall Street Zen - MarketBeat
Zacks Research Downgrades Monopar Therapeutics (NASDAQ:MNPR) to Hold - MarketBeat
Equities Analysts Offer Predictions for MNPR FY2029 Earnings - MarketBeat
Buy Rating Reiterated on Monopar as ALXN-1840 Advances in Wilson Disease; $125 Price Target Maintained - TipRanks
Monopar Therapeutics Shares Drop After Downgrade From Cantor Fitzgerald - marketscreener.com
Monopar downgraded to Neutral at Cantor (MNPR:NASDAQ) - Seeking Alpha
This Stubhub Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday - Benzinga
MNPR Maintained by Barclays -- Price Target Raised to $128.00 - GuruFocus
MNPR Downgraded by Cantor Fitzgerald -- Price Target Raised to $119 - GuruFocus
Monopar Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Cantor downgrades Monopar stock on valuation after 90% rally - Investing.com
Cantor downgrades Monopar stock on valuation after 90% rally By Investing.com - Investing.com Canada
Boris Peaker Maintains Buy Rating on Monopar, Reaffirming Unchanged $130 Price Target on ALXN1840’s Strong Clinical and Regulatory Profile - TipRanks
Saturn V Capital shows sub-5% Monopar Therapeutics (MNPR) stake in 13G/A - Stock Titan
Monopar Therapeutics stock price target raised to $133 by BTIG - Investing.com Canada
MNPR Maintained by BTIG -- Price Target Raised to $133 - GuruFocus
BTIG Research Forecasts Strong Price Appreciation for Monopar Therapeutics (NASDAQ:MNPR) Stock - MarketBeat
Monopar Therapeutics (NASDAQ:MNPR) Issues Quarterly Earnings Results, Misses Expectations By $0.13 EPS - MarketBeat
Adage Capital discloses 4.76% Monopar Therapeutics (MNPR) stake including warrants - Stock Titan
Form 8K Monopar Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
Monopar Therapeutics' Q2 Net Loss Widens - marketscreener.com
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update on ALXN1840 NDA Submission - Quiver Quantitative
Monopar Reports Q2 2026 Net Loss of $5.3 Million - Quiver Quantitative
Monopar Therapeutics reports Q2 2026: $5.3M net loss, $134.3M cash on hand - TradingView
Monopar Therapeutics 2Q 2026: Net income $(5.31M), EPS $(0.62) — 10-Q Summary - TradingView
Monopar Therapeutics (MNPR) deepens R&D spend but retains $134M cash runway - Stock Titan
Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen - MarketBeat
Monopar Therapeutics Inc. expected to post a loss of 62 cents a shareEarnings Preview - TradingView
Bank of New York Mellon Corp Has $4.31 Million Position in Monopar Therapeutics Inc. $MNPR - MarketBeat
Why is Monopar Therapeutics stock up today? Resistance levels in focus - Traders Union
Monopar Therapeutics (NASDAQ:MNPR) Sets New 1-Year HighWhat's Next? - marketbeat.com
MNPR Q2'26 Earnings: EPS estimate is (0.66) USD - TradingView
Monopar Therapeutics stock approaches $125.77 resistance as bullish momentum drives gains - Traders Union
Monopar Therapeutics (MNPR) Projected to Post Earnings on Tuesday - MarketBeat
Monopar Therapeutics stock closes near session high as buyers regain control - tradersunion.com
Why is Monopar Therapeutics stock down today? Key support levels to watch - Traders Union
Monopar Therapeutics (NASDAQ:MNPR) Reaches New 52-Week HighWhat's Next? - MarketBeat
MNPR Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Monopar Therapeutics (MNPR) Slips Slightly as Biotech Sector Faces Profit-TakingETF NAV Deviation - dars.gov.et
Monopar Therapeutics Inc (MNPR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Monopar Therapeutics Inc (MNPR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Monopar Therapeutics Inc (MNPR) Institutional Confidence - TradingKey
Monopar Therapeutics Inc (MNPR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Monopar Therapeutics Inc (MNPR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MNPR|Monopar Therapeutics Inc|Price:110.450|Chg%:+0.580 - TradingKey
Monopar Therapeutics Inc (MNPR) Cash Flow - TradingKey
BTIG’s Mukherjee Initiates Buy on Monopar Therapeutics, Citing Emerging Head & Neck Cancer Data and Favorable Risk‑Reward Setup - TipRanks
MONOPAR THERAPEUTICS INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $125 FROM $105 - webull.com
Walleye Capital LLC Takes Position in Monopar Therapeutics Inc. $MNPR - MarketBeat
Why is Monopar Therapeutics stock down 7.6% today? - Traders Union
Monopar Therapeutics Inc. (MNPR) stock price, news, quote and history - Yahoo Finance UK
Morgan Stanley Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $115 - Moomoo
H.C. Wainwright raises Monopar stock price target to $125 on NDA filing - Investing.com
Barclays Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $125 - Moomoo
MNPR Maintained by HC Wainwright & Co. -- Price Target Raised to $125 - GuruFocus
Monopar Therapeutics (MNPR) Proxy Filing Summary - Quartr
Maldonado Reiterates Buy on Monopar as ALXN1840 NDA Progress and Robust Clinical Data Drive Price Target Increase from $105 to $125 - TipRanks
H.C. Wainwright Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $125 - Moomoo
Monopar Therapeutics Begins Rolling Application for ALXN1840 in Wilson Disease - Moomoo
Monopar Begins Rolling FDA NDA Submission for ALXN1840 - TipRanks
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease - The Manila Times
ALXN1840 Could Be First U.S. Wilson Therapy With Novel Mechanism in Decades - Stock Titan
HC Wainwright Issues Positive Forecast for Monopar Therapeutics (NASDAQ:MNPR) Stock Price - MarketBeat
Can leadership appointments spark further gains for Monopar Therapeutics stock? - Traders Union
Monopar adds commercial leaders ahead of drug filing By Investing.com - Investing.com Nigeria
1.80%
1.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):